154 related articles for article (PubMed ID: 22392423)
1. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Sandkovsky U; Swindells S; Moore R; Acosta EP; Fletcher CV
Pharmacotherapy; 2012 Feb; 32(2):142-7. PubMed ID: 22392423
[TBL] [Abstract][Full Text] [Related]
2. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Do VT; Higginson RT; Fulco PP
Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
[TBL] [Abstract][Full Text] [Related]
4. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
[TBL] [Abstract][Full Text] [Related]
5. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Wohl DA; Dumond JB; Blevins S; Pittard D; Ragan D; Wang R; Massengale K; Walsh K; Floris-Moore M; Eron JJ; Richardson A; Hudgens MG; Kashuba AD
Antimicrob Agents Chemother; 2013 Feb; 57(2):784-8. PubMed ID: 23183440
[TBL] [Abstract][Full Text] [Related]
7. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
[TBL] [Abstract][Full Text] [Related]
8. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
[TBL] [Abstract][Full Text] [Related]
9. Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum.
Burger D; Krens S; Robijns K; Aarnoutse R; Brüggemann R; Touw D
Ther Drug Monit; 2014 Dec; 36(6):824-7. PubMed ID: 24819970
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A; Dutta S; Dunbar M; Podsadecki T; Trinh R; Awni W; Menon R
Antimicrob Agents Chemother; 2016 May; 60(5):2965-71. PubMed ID: 26953200
[TBL] [Abstract][Full Text] [Related]
11. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
[TBL] [Abstract][Full Text] [Related]
12. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
Brooks KM; Garrett KL; Kuriakose SS; George JM; Balba G; Bailey B; Anderson M; Lane HC; Maldarelli F; Pau AK
Pharmacotherapy; 2017 Aug; 37(8):e82-e89. PubMed ID: 28556353
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W; Lalezari J; Sension MG; Wohlfeiler M; Gathe J; Appelbaum JS; Bellman P; Gottlieb MS; Ryan R; Nijs S; Hoogstoel A; Van Solingen-Ristea R; Witek J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):614-8. PubMed ID: 20134329
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
[TBL] [Abstract][Full Text] [Related]
15. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
[TBL] [Abstract][Full Text] [Related]
16. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
Nakamura H; Miyazaki N; Hosoya N; Koga M; Odawara T; Kikuchi T; Koibuchi T; Kawana-Tachikawa A; Fujii T; Miura T; Iwamoto A
J Infect Chemother; 2011 Feb; 17(1):105-10. PubMed ID: 20585968
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
[TBL] [Abstract][Full Text] [Related]
18. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
19. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
20. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R; Allavena C; Peytavin G; Soulie C; Tubiana R; Weiss L; Montoya Ferrer A; Duvivier C; Bouchaud O; Bottero J; Durand A; Lê MP; Marcelin AG; Dudoit Y; Assoumou L; Katlama C;
J Antimicrob Chemother; 2021 Jan; 76(2):477-481. PubMed ID: 33099638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
